# CJC-1295: Research Overview — Peptide Scienes > A reported look at CJC-1295, the long-acting growth-hormone-releasing hormone analog identified by anti-doping chemists in 2010. Mechanism, human pharmacokinetic data, community-reported effects, and cited safety cautions. A modified growth-hormone-releasing hormone analog that a 2010 anti-doping lab caught hiding inside an unlabeled preparation — and the closest thing on this desk to a cautionary tale. ## The short version CJC-1295 is a lab-made version of growth-hormone-releasing hormone (GHRH) — the natural signal that tells the pituitary gland, a small hormone-producing organ at the base of the brain, to release growth hormone. Ordinary GHRH breaks down in the bloodstream within minutes. CJC-1295 has been chemically reinforced to resist that breakdown, and one version of it — called the DAC form — is further modified to latch onto a blood protein called albumin, stretching its effect from minutes to days. It is not an approved medicine anywhere. The only published human studies are small, short pharmacology trials from the 2000s that measured hormone levels in healthy volunteers, not therapeutic trials in patients [4][5]. This page walks through what those studies actually found, what people report using it for outside a lab setting, and why regulators have specifically flagged it as a safety concern — all without recommending a dose for anyone. ## What it is CJC-1295 starts from the first 29 amino acids of human GHRH — the fragment known to retain full biological activity — and carries four substitutions that lock the peptide into a more stable spiral shape and block the enzyme (dipeptidyl peptidase-IV) that would otherwise chew through it within minutes. That gives the base molecule, sometimes sold as "Modified GRF 1-29" or CJC-1295 no-DAC, a working life of minutes to a few hours instead of the roughly seven minutes of native GHRH. The better-known DAC version goes a step further. A chemical linker on the peptide's tail reacts with a specific site on circulating albumin — the most abundant protein in blood plasma — and forms a stable bond. Because albumin itself circulates for weeks, the attached peptide inherits something close to that lifespan, which is why a single injection of CJC-1295 DAC can keep growth hormone elevated for multiple days rather than minutes [4]. "CJC-1295" is used online to mean either version, and the difference between them is not cosmetic — it changes the entire risk and exposure picture. ## How it works CJC-1295 binds the growth-hormone-releasing hormone receptor on somatotroph cells in the anterior pituitary, switching on a signaling cascade — through a G-protein called Gs, the enzyme adenylyl cyclase, and a second messenger called cAMP — that triggers those cells to both make and release growth hormone. That growth hormone then travels to the liver, where it stimulates production of insulin-like growth factor-1 (IGF-1), the hormone that carries out much of GH's actual work in tissue throughout the body. What is notable mechanistically is that CJC-1295 does not flood the system with growth hormone at a flat, unnatural level. A 2006 human study found that even under continuous CJC-1295 stimulation, growth hormone was still released in its normal pulsatile pattern rather than as a constant elevation — the frequency and shape of the natural pulses were preserved, just riding on a higher baseline [5]. That is a meaningfully different pharmacological story from injecting recombinant growth hormone directly, which does not reproduce the body's own release rhythm. ## What the research shows The most current framing of this drug class comes from a 2025 Nature Reviews Endocrinology paper covering how GHRH and its synthetic analogs — including CJC-1295, sermorelin, and tesamorelin — signal through the GHRH receptor and where each stands therapeutically [1]. CJC-1295 entered the peer-reviewed record not through a clinical trial but through forensic chemistry: in 2010, anti-doping laboratory scientists ran high-resolution mass spectrometry on an unlabeled "GHRH" preparation and identified the active ingredient as CJC-1295 — a direct chemical identification, not an inference from a label [2]. The human pharmacology data, while limited, is consistent. In eleven healthy men, CJC-1295 shifted several blood proteins in a pattern that tracked linearly with IGF-1, suggesting a usable biomarker for GH-axis activation [3]. The core dose-response study, in adults aged 21 to 61, found single doses of 30 to 60 micrograms per kilogram produced two- to ten-fold increases in growth hormone lasting six days or more, and IGF-1 elevated for nine to eleven days after a single dose — up to 28 days with repeated dosing — with an estimated peptide half-life of 5.8 to 8.1 days [4]. A companion study in men aged 20 to 40 found growth hormone's normal pulsatile release pattern persisted unchanged under continuous CJC-1295 stimulation, just riding a higher baseline [5]. What's absent from that list is just as telling: no trial has tested CJC-1295 for a specific health outcome, against a comparison treatment, or for longer than several weeks. ## Reported effects, cautions & safety People in research-use and fitness communities describe a fairly consistent set of experiences with CJC-1295 — and it bears repeating clearly that these are **anecdotal, not clinical evidence**, drawn from forum posts and clinic write-ups, not controlled studies. The benefit reported most often, by a wide margin, is deeper, more restful sleep, often the very first change people notice — which lines up with growth hormone being released mainly during deep sleep. Faster workout recovery, gradual midsection fat loss appearing after three to six weeks, and a leaner look while dieting follow close behind; more daytime energy and sharper focus come up less consistently. The downside reports cluster just as tightly. Water retention — bloating, puffiness, a heavier feeling — is the single most common complaint, and it is widely described as worse with the long-acting DAC form than the short-acting no-DAC version, consistent with DAC keeping growth hormone elevated for days rather than hours. Tingling or numbness in the fingers, often compared to mild carpal tunnel, is frequently linked to that same fluid retention. Injection-site reactions, occasional flushing after a no-DAC dose, fatigue with the DAC form, headache, and a smaller number of self-reported blood-sugar changes round out the picture. Against that anecdotal backdrop, the documented cautions are narrower but weightier. Published human evidence is limited to a handful of short early-phase studies rather than any long-term safety trial, so CJC-1295 should be treated as investigational, not proven safe [4]. A 2024 FDA advisory-committee review cited immunogenicity concerns among the reasons for not recommending GHRH analogs like CJC-1295 for a compounding-bulks list [1]. The compound's own history adds a further data point: its original long-acting development program was discontinued after a halted Phase 2 trial, and it is prohibited in sport at all times under the World Anti-Doping Agency's rules — a regulatory risk distinct from any health question. ## Where it fits in Research Peptide Fundamentals CJC-1295 belongs on this desk as the cautionary half of a two-peptide GHRH story. It shares its exact receptor target with [tesamorelin](/tesamorelin) — both drive the pituitary to release more of the body's own growth hormone rather than supplying growth hormone directly — but the two compounds have landed in nearly opposite places: tesamorelin cleared FDA approval for a specific condition, while CJC-1295 remains a research chemical with a discontinued development history and an FDA committee flagging its immunogenicity [1][19]. Reading them together answers a question neither page answers alone: what actually separates an approved GHRH analog from one that never advanced. See the [full comparison](/compare) for how both stack up against GHK-Cu and semaglutide as well. ![CJC-1295 research illustration — abstract GHRH receptor motif in graphite and cobalt](/images/cjc-1295.webp) --- An investigative reading file on research peptides — every claim traced to its source, every gap named, revised whenever the record moves.